| Literature DB >> 24253417 |
Jeffrey E Roth1, Cody J Peer1, Douglas K Price1, William D Figg1.
Abstract
The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. Its transcriptional activity has previously been studied in cell lines. A group at the University of Cambridge recently outlined the AR transcriptional program in tissue samples, with an emphasis on castration-resistant tumors. AR binding sites, gene-expression changes (in xenografts), and potential transcription factor interactions were notably different from those observed in cultured cells. These discrepancies suggest a distinct signaling network for the AR in vivo and serve as a reminder that results from in vitro models should be checked against clinical realities.Entities:
Keywords: androgen receptor; binding site; castration-resistant prostate cancer; transcription factor; transcriptional program
Mesh:
Substances:
Year: 2013 PMID: 24253417 PMCID: PMC3938517 DOI: 10.4161/cbt.27149
Source DB: PubMed Journal: Cancer Biol Ther ISSN: 1538-4047 Impact factor: 4.742